Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency-Real World Evidence

Nadarajah, Nageswary; Ssemmondo, Emmanuel; Brooks, Shani; Akinyombo, Remi; Adeleke, Kazeem; Deshmukh, Harshal; Sathyapalan, Thozhukat

Abstract

Background: Growth hormone replacement is indicated in adults with severe growth hormone (GH) deficiency, adult growth hormone deficiency assessment (AGHDA) score of at least 11 and are receiving treatment for other pituitary hormone deficiencies. There are no data looking at the cessation of GH replacement in adult patients with severe GH deficiency and the factors that predict the likelihood of patients continuing or stopping growth hormone replacement. Methods: We audited patients on the GH register between January 2006 and January 2023 in Hull University Teaching Hospitals NHS foundation Trust, a UK tertiary hospital. Baseline characteristics, the cause of GH deficiency, AGHDA score at diagnosis and the reason for stopping GH were collected. Proportions were compared between patients adhering to GH replacement and those who had ceased it. Logistic regression analysis was used to identify factors independently associated with cessation of GH. Results: The study comprised 141 adult patients with a mean age of 52 years, of which 75 (53%) were female. 54 (38%) individuals had discontinued GH replacement therapy. Predominant reasons for discontinuation were lack of therapeutic benefit (46%) and a change in clinical indication (26%). Among patients who discontinued GH therapy, the most frequent cause of GH deficiency was idiopathic (57%), while for those on GH replacement, pituitary surgery was the leading cause of GH deficiency (53%). Logistic regression analysis showed no baseline factor was statistically significantly associated with GH cessation, except female gender which had a borderline significance (P = 0.05). Conclusions: In this real-world investigation of patients with severe GH deficiency, over two in five individuals who discontinued GH therapy cited the absence of perceived benefits. We show a borderline association of female gender with GH cessation and large population-based studies will be needed to investigate this and other causes of GH cessation.

Citation

Nadarajah, N., Ssemmondo, E., Brooks, S., Akinyombo, R., Adeleke, K., Deshmukh, H., & Sathyapalan, T. (2024). Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency-Real World Evidence. International Journal of Endocrinology and Metabolism, 22(3), Article e147825. https://doi.org/10.5812/ijem-147825

• Journal Article Type: Article
• Acceptance Date: Sep 17, 2024
• Online Publication Date: Oct 27, 2024
• Publication Date: Jul 1, 2024
• Deposit Date: Dec 15, 2024
• Publicly Available Date: Dec 16, 2024
• Journal: International Journal of Endocrinology and Metabolism
• Print ISSN: 1726-913X
• Electronic ISSN: 1726-9148
• Peer Reviewed: Peer Reviewed
• Volume: 22
• Issue: 3
• Article Number: e147825
• DOI: https://doi.org/10.5812/ijem-147825
• Keywords: Growth hormone; Clinical factors; Therapy cessation
• Public URL: https://hull-repository.worktribe.com/output/4922672